welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)
study id #: NCT03907072
condition: Duchenne Muscular Dystrophy
status: terminated
purpose:This is a Phase 2/3, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension period to evaluate the safety and efficacy of WVE-210201 (suvodirsen) in ambulatory male pediatric patients with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping intervention (DYSTANCE 51)
intervention: WVE-210201 (Suvodirsen), Placebo
mechanism of action: Exon-skipping to promote dystrophin production
results: https://clinicaltrials.gov/ct2/show/results/NCT03907072
last updated: January 31, 2020
rareRelated
-
Small Mutation Screening in the DMD Gene by Whole Exome Sequencing of an Argentine Duchenne/Becker Muscular Dystroph...Dystrophinopathies are neuromuscular X-l...
-
Wave Life Sciences Receives US Orphan Drug and Rare Pediatric Disease Designations for WVE-210201Wave Life Sciences Ltd., a biotechnology...
-
Peptide-Conjugate Antisense Based Splice-Correction for Duchenne Muscular Dystrophy and Other Neuromuscular DiseasesDuchenne muscular dystrophy (DMD) is an ...
-
Results at 96 Weeks of a Phase IIb Extension Study of the Exon-Skipping Drug Eteplirsen in Patients with Duchenne Mu...Objective: The objective of this study ...
-
Dublin boy paves the way for new muscle disease treatmentA Dublin boy has become a pioneer in how...
-
Empirical and Computational Comparison of Alternative Therapeutic Exon Skip Repairs for Duchenne Muscular DystrophyDuchenne muscular dystrophy (DMD) is a c...
-
Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)The aim of this study is to provide cont...